Follow
Elizabeth Christie
Elizabeth Christie
Peter MacCallum Cancer Centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
Whole–genome characterization of chemoresistant ovarian cancer
AM Patch, EL Christie, D Etemadmoghadam, DW Garsed, J George, ...
Nature 521 (7553), 489-494, 2015
11812015
Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
EL Christie, S Fereday, K Doig, S Pattnaik, SJ Dawson, DDL Bowtell
Journal of Clinical Oncology 35 (12), 1274-1280, 2017
1462017
Pan-cancer analysis of whole genomes.
S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ...
Nature 578 (DKFZ-2020-01051), 82-93, 2020
1322020
Acquired chemotherapy resistance in ovarian cancer
EL Christie, DDL Bowtell
Annals of Oncology 28, viii13-viii15, 2017
1032017
LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin
PA Cowin, J George, S Fereday, E Loehrer, P Van Loo, C Cullinane, ...
Cancer research 72 (16), 4060-4073, 2012
982012
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes
SC Dentro, I Leshchiner, K Haase, M Tarabichi, J Wintersinger, ...
Cell 184 (8), 2239-2254. e39, 2021
972021
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
EL Christie, S Pattnaik, J Beach, A Copeland, N Rashoo, S Fereday, ...
Nature communications 10 (1), 1-10, 2019
852019
Mechanisms of drug resistance in high-grade serous ovarian cancer
AE Freimund, JA Beach, EL Christie, DDL Bowtell
Hematology/Oncology Clinics 32 (6), 983-996, 2018
742018
A community-based model of rapid autopsy in end-stage cancer patients
K Alsop, H Thorne, S Sandhu, A Hamilton, C Mintoff, E Christie, O Spruyt, ...
Nature biotechnology 34 (10), 1010-1014, 2016
582016
Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian CancerExceptional …
DW Garsed, K Alsop, S Fereday, C Emmanuel, CJ Kennedy, ...
Clinical Cancer Research 24 (3), 569-580, 2018
522018
Ovarian carcinoma-associated mesenchymal stem cells arise from tissue-specific normal stroma
LG Coffman, AT Pearson, LG Frisbie, Z Freeman, E Christie, DD Bowtell, ...
Stem Cells 37 (2), 257-269, 2019
452019
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian CarcinomasEIF1AX and NRAS Mutations in Low-Grade Serous Ovarian Cancer
D Etemadmoghadam, WJ Azar, Y Lei, T Moujaber, DW Garsed, ...
Cancer Research 77 (16), 4268-4278, 2017
452017
Abnormal nuclear pore formation triggers apoptosis in the intestinal epithelium of elys-deficient zebrafish
TA de Jong–Curtain, AC Parslow, AJ Trotter, NE Hall, H Verkade, ...
Gastroenterology 136 (3), 902-911. e7, 2009
432009
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer
T O’Donnell, EL Christie, A Ahuja, J Buros, BA Aksoy, DDL Bowtell, ...
BMC cancer 18 (1), 1-11, 2018
302018
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerAnti-apoptotic Genes in Ovarian Cancer Drug Resistance
EH Stover, MB Baco, O Cohen, YY Li, EL Christie, M Bagul, A Goodale, ...
Molecular Cancer Research 17 (11), 2281-2293, 2019
202019
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer
A Nath, PA Cosgrove, H Mirsafian, EL Christie, L Pflieger, B Copeland, ...
Nature communications 12 (1), 1-16, 2021
92021
Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell CancerTargeting IL6 Signaling in OCCA
WJ Azar, EL Christie, C Mitchell, DS Liu, G Au-Yeung, DDL Bowtell
Cancer Research 80 (22), 4960-4971, 2020
92020
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer
N Rinne, EL Christie, A Ardasheva, CH Kwok, N Demchenko, C Low, ...
Cancer Drug Resistance 4 (3), 573, 2021
62021
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
E Morrish, A Copeland, DM Moujalled, JA Powell, N Silke, A Lin, ...
Blood advances 4 (20), 5062-5077, 2020
62020
Blood worth bottling: circulating tumor DNA as a cancer biomarker
EL Christie, SJ Dawson, DDL Bowtell
Cancer Research 76 (19), 5590-5591, 2016
62016
The system can't perform the operation now. Try again later.
Articles 1–20